Heart surgery safe for compensated cirrhosis patients

April 27, 2012
Heart surgery safe for compensated cirrhosis patients

(HealthDay) -- Patients with compensated cirrhosis, defined by a Child-Pugh (CP) score of <8, have no significant increase in postoperative mortality and morbidity following cardiac surgery with cardiopulmonary bypass, according to a study published in the May issue of Clinical Gastroenterology and Hepatology.

To investigate the effect of on mortality and morbidity after cardiac surgery, Carole Macaron, M.D., of the Cleveland Clinic, and colleagues conducted a of 54 patients with cirrhosis and 216 matched controls without cirrhosis. All participants underwent cardiac surgery with cardiopulmonary bypass at the same institution between 1992 and 2009. For patients with cirrhosis, the CP class and score were calculated.

The researchers found that, within 90 days of surgery, the mortality rate was 4.6 percent for those with a CP score <8, similar to that observed in control patients without cirrhosis, and significantly lower than the mortality rate for patients with a CP score of ≥8 (70 percent). Hospital stays were significantly shorter for patients with CP scores <8, (15.6 days, versus 26 days for those with CP scores ≥8). Renal failure and the need for dialysis were significantly less likely in those with CP scores <8. These values were similar to those of matched controls.

"Among the patients with liver cirrhosis, patients with CP score <8 might safely undergo with cardiopulmonary bypass," the authors write. "Our study shows that such patients had similar outcomes in terms of mortality and morbidity compared with their matched controls."

Explore further: Study suggests obesity accelerates progression of cirrhosis

More information: Abstract
Full Text (subscription or payment may be required)
Editorial

Related Stories

Study suggests obesity accelerates progression of cirrhosis

July 21, 2011

Researchers from the United States and Europe involved in an NIH-funded multicenter study have determined that increased body mass index (BMI) is an independent predictor of clinical decompensation in patients with compensated ...

The economic cost of advanced liver disease

November 7, 2011

Health care costs for hepatitis C patients with end-stage liver disease are nearly 2.5 times higher than those in the early stages, according to a Henry Ford Hospital study.

Recommended for you

Bile acid uptake inhibitor prevents NASH / fatty liver in mice

September 21, 2016

Drugs that interfere with bile acid recycling can prevent several aspects of NASH (nonalcoholic steatohepatitis) in mice fed a high-fat diet, scientists from Emory University School of Medicine and Children's Healthcare of ...

New therapeutic target for Crohn's disease

September 20, 2016

Research from the Sanford Burnham Prebys Medical Discovery Institute (SBP) identifies a promising new target for future drugs to treat inflammatory bowel disease (IBD). The study, published today in Cell Reports, also indicates ...

Mosquitoes, Zika and biotech regulation

September 19, 2016

In a new Policy Forum article in Science, NC State professor Jennifer Kuzma argues that federal authorities are missing an opportunity to revise outdated regulatory processes not fit for modern innovations in biotechnology, ...

Arthritis drug may help with type of hair loss

September 22, 2016

(HealthDay)—For people who suffer from a condition that causes disfiguring hair loss, a drug used for rheumatoid arthritis might regrow their hair, a new, small study suggests.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.